Azitra to present at H.C. Wainwright conference; update on ATR-COSF and ATR-04

Azitra, Inc.

COO Travis Whitfill to present virtually at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.
Presentation will include initial data from ATR-COSF program for cosmetic applications targeting fine lines and wrinkles.
Will discuss continued enrollment in first cohort of Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash.
ATR-04 has FDA Fast Track designation; EGFRi rash impacts ~150,000 people in U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.